![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » OGD Reports Continued Increase in First-Time Generic Approvals in 2018
OGD Reports Continued Increase in First-Time Generic Approvals in 2018
March 6, 2019
The FDA’s Office of Generic Drugs released its annual report for 2018, highlighting a steady increase in first-time generic approvals and the green lighting of more than 1,000 generic drugs.
OGD’s outgoing Director Kathleen Uhl — who retired in February after two decades with the agency — called 2018 “an extremely successful year,” noting that the agency approved or tentatively approved a total of 1,021 ANDAs, with first generics accounting for approximately 10 percent and complex generics comprising roughly 14 percent.
The office approved 88 first-time generics for the year, compared to 80 the previous year and 73 in 2016. Significant 2018 approvals included first-time generics for Suboxone (buprenorphine and naloxone), Zortress (everolimus) and EpiPen (epinephrine).
Upcoming Events
-
21Oct